HC Wainwright&Co.:上调Dogwood Therapeutics(DWTX.US)评级,由中性调整至买入评级,目标价10.00美元。Dogwood Therapeutics(DWTX.US)公司简介:Dogwood Therapeutics Inc前身为Virios Therapeutics Inc,是一家处于开发阶段的生物技术公司。该公司专注于推进新型抗病毒疗法,以治疗与病毒引发...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.